RNS Number : 2516B
Integrated Diagnostics Holdings PLC
01 June 2023

Integrated Diagnostics Holdings Plc
Q1 2023 Results
Thursday, 01 June 2023

Integrated Diagnostics Holdings Plc kicks off 2023 with a solid quarter, recording 43% growth in conventional revenues

(Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading pro diagnostic services with operations in Egypt, Jordan, Nigeria and Sudan, released today its reviewed financial sta and operational performance for the quarter ended 31 March 2023, booking revenue of EGP 915 million, 22% revenues reported in the first quarter of the previous year when Covid-19-related[1] testing had significantly boos consolidated figure. Excluding[2] the contribution made by Covid-19-related testing in the comparable three mo 2022, the Group's conventional[3] revenues recorded an impressive 43% year-on-year expansion supported by year-on-year increase in conventional test volumes and a 27% year-on-year increase in average reven conventional test for the quarter. IDH recorded a net profit of EGP 168 million, declining 46% from Q1 2022 and associated margin of 18%.

Financial Results (IFRS)[4]

EGP mn	Q1 2022	Q
Revenues	**1,180**	
Conventional Revenues	*640*	
Covid-19-related Revenues	*540*	
Cost of Sales	(649)	
Gross Profit	**532**	
Gross Profit Margin	*45%*	
Operating Profit	396	
EBITDA5	**468**	
EBITDA Margin	*40%*	
Net Profit	**314**	
Net Profit Margin	*27%*	
Cash Balance	**2,659**	

Note (1): Throughout the document, percentage changes between reporting periods are calculated using the exact value (as per the Consolidated Financials) and not the corresponding rour

Key Operational Indicators[6]

	Q1 2022
Branches	520
Patients ('000)	2,649
Revenue per Patient (EGP)	446
Tests ('000)	8,402
Conventional Tests ('000)	*7,148*
Covid-19-related Tests ('000)	*1,254*

Revenue per Test	140
Revenue per Conventional Test (EGP)	*90*
Revenue per Covid-19-related Test (EGP)	*431*
Test per Patient	3.2

1Covid-19-related tests include both core Covid-19 tests (Polymerase Chain Reaction (PCR), Antigen, and Antibody) as well as other routine inflammatory a markers including, but not limited to, Complete Blood Picture, Erythrocyte Sedimentation Rate (ESR), D-Dimer, Ferritin and C-reactive Protein (CRP), which th opted to include in the classification as "other Covid-19-related tests" due to the strong rise in demand for these tests witnessed following the outbreak of Covid-19
2Starting Q1 2023, IDH has opted to stop reporting on its Covid-19-related revenues and test volumes due to their material insignificance to the consolidated fig Egypt's and Jordan's country-level results for the quarter. In the comparable period of last year (Q1 2022) IDH had recorded EGP 540 million in Covid-19-relate and had performed 1.3 million Covid-19-related tests.
3Conventional (non-Covid) tests include all of the Group's test offering with the exception of its Covid-19-related test offering outlined above.
4Important notice: In the Company's earnings releases covering the five quarters starting from Q4 2021 and ending Q4 2022, management had opted to present Performance Measures (APM) alongside IFRS-compliant figures as outlined on page 2 of the Company's FY 2022 Earnings Release. Starting in Q1 2023, due to insignificance of Covid-19-related revenues on consolidated results, the Company will only report IFRS-compliant figures. It is worth noting that revenues for the period (Q1 2022), include concession fees amounting to EGP 63 million paid by Biolab as part of its agreement with QAIA and Aqaba Port.
5EBITDA is calculated as operating profit plus depreciation and amortization.
6Key operational indicators are calculated based on revenues for the quarter of EGP 915 million and EGP 1,180 million for Q1 2023 and Q1 2022, respectively.

Introduction

i. Financial Highlights

•€€€ **Conventional[7] revenue** recorded EGP 915 million in Q1 2023 compared to EGP 640 million (ir concession fees paid as part of Biolab's agreements with QAIA, KHIA, and Aqaba Port amounting to million) in the same period of the previous year, representing an impressive 43% year-on-year growth.

•€€€ Conventional top-line growth continues to be driven by simultaneous rises in test volumes and revenue per test, which in Q1 2023 increased 12% and 27% year-on-year, respectively. It is worth high that a portion of the rise in average revenue per test reflects the translation effect resulting from the devaluations of the Egyptian Pound during FY 2022 and the beginning of FY 2023.

•€€€ **Consolidated revenues** recorded EGP 915 million in Q1 2023 contracting 22% from the high base 1,180 million in Q1 2022. It is important to note that the comparable three months of 2022 included a si EGP 540 million contribution (46% of Q1 2022 revenues) from IDH's Covid-19-related[8] offering in Eg Jordan (of which EGP 63 million related to concession fees paid by Biolab to Queen Alia International Air Aqaba Port).

•€€€ **Gross Profit** booked EGP 325 million in Q1 2023, down 39% year-on-year, with a Gross Profit Margin of 35% in Q1 2023 versus 45% in Q1 2022. Lower gross profitability during the quarter primarily re normalisation of margins following the year-on-year decline in Covid-19-related business which had sign boosted revenue and profitability in Q1 2022. Gross margins were further diluted by higher direct sala wages to counteract the current inflationary pressures and staff the newly rolled out branches.

•€€€ **EBITDA[9]** stood at EGP 227 million during Q1 2023, declining 51% year-on-year and recording an margin of 25% versus 40% in Q1 2022. Decreased EBITDA profitability for the period came on the back gross profitability combined with increased SG&A outlays including higher salary, marketing, auditi consulting expenses. The rise in auditing and consulting expenses is partially attributable to a weaker EG

•€€€ **Net Profit** for the three-month period ended 31 March 2023 booked EGP 168 million, down 46% year and with an associated Net Profit Margin (NPM) of 18%.

7Conventional (non-Covid) tests include IDH's full service offering excluding the Covid-19 related tests outlined below.
8Covid-19-related tests include both core Covid-19 tests (Polymerase Chain Reaction (PCR), Antigen, and Antibody) as well as other routine inflammatory a markers including, but not limited to, Complete Blood Picture, Erythrocyte Sedimentation Rate (ESR), D-Dimer, Ferritin and C-reactive Protein (CRP), which th opted to include in the classification as "other Covid-19-related tests" due to the strong rise in demand for these tests witnessed following the outbreak of Covid-19
9EBITDA is calculated as operating profit plus depreciation and amortization.

ii. Operational Highlights

•€€€ IDH's **branch network** increased to 576 branches in Q1 2023, up by 56 branches compared to th period of the previous year. Since the start of the year, IDH has inaugurated 24 new branches includin Egypt, three in Jordan, and one in Sudan.

•€€€ **Conventional tests** performed during Q1 2023 increased by 12% year-on-year to record 8.0 million the quarter. Consolidated tests performed for the period declined 4% year-on-year, as Q1 2022 test include a significant contribution for IDH's Covid-19-related offering.

•€€€ **Average net revenue per conventional test** increased a robust 27% (out of which translatio accounted for 9%) versus Q1 2022 to book EGP 114 in Q1 2023. Consolidated average net revenue declined 19% to EGP 114 in Q1 2022 from the EGP 140 recorded in the same quarter a year ag consolidated results had been boosted by significant contributions made by IDH's generally higher-pricec 19-related offering.

- €€€ **Total patients served** by the Company during the quarter came in at 1.9 million, down 27% year- Simultaneously, average test per patient increased to 4.1 in Q1 2023 from 3.2 in Q1 2022 largely refl normalisation in IDH's patient mix in favour of conventional patients who typically opt for multiple tes visiting IDH's branches.
- €€€ In **Egypt** (79.9% of consolidated revenues) IDH continued to record robust growth at its conv business, which expanded 33% year-on-year for the quarter. Conventional revenue growth was suppor 13% year-on-year rise in test volumes and an 18% year-on-year increase in average revenue p Meanwhile, consolidated revenues in IDH's home market declined 17% versus Q1 2022 when results h boosted by contributions made from the Company's Covid-19-related offering (38% of Egypt revenue 2022).
- €€€ In **Jordan** (15.8% of consolidated revenues), the Group recorded conventional revenue growth in EG of 105% year-on-year in Q1 2023. In local currency terms, conventional revenues also posted a remarka year-on-year expansion on the back of higher conventional test. Including contributions from Covid-19 testing in the first three months of last year, consolidated revenues in Jordan recorded a 48% year- decline during Q1 2023.
- €€€ In **Nigeria** (3.4% of consolidated revenue in Q1 2023), the Company continued recording impressive growth, increasing 109% year-on-year to EGP 31 million in Q1 2023. In NGN terms, revenue increas year-on-year to reach NGN 468 million during Q1 2023, supported by a 16% increase in test volumes.
- €€€ In **Sudan** (1.0% of consolidated revenue in Q1 2023), IDH posted an impressive year-on-year revenue of 55% in EGP terms, and 11% in SDG terms. It is important to note that due to recent political unrest in 16 of IDH's 18 branches in Sudan have temporarily ceased operations, with only two branches, in Mad Port Sudan, still operational. The closure of these branches will have a significant impact on Sudan's ope and financial results for the coming quarter.

iii. Management Commentary

Commenting on the Group's performance, IDH Chief Executive Officer Dr. Hend El-Sherbini said: "With the months of the year now behind us, I am happy to report another quarter of sustained growth at our conventional b and of solid progress on our longer-term value creation and growth strategies. Looking at our results for the first of the year in more detail, I am particularly pleased to note that we recorded solid conventional top-line exp across all four of our markets in both EGP and local currency terms. At the consolidated level, conventional growth was driven by steady rises in both patient and test volumes coupled with rising average revenue per tes strategic price hikes come into effect. The 43% year-on-year expansion of our conventional business was es impressive as it comes in the midst of an increasingly difficult operating environment with our markets, and th economy in general, continuing to face rising inflation, tightening monetary policies, and weakening currencies, the case in Egypt, Nigeria, and Sudan. On top of this, it is worth noting that our results in March were also impa the expected seasonal slowdown related to the holy month of Ramadan which in 2023 weighed on patient starting mid-March.

On a geographic basis, across our two largest markets of Egypt and Jordan, conventional revenues continued t double-digit growth showcasing the underlying health of both geographies. Since the start of the year, we deliv several of our key strategic priorities across both markets. In Egypt, in the first three months of the year we rolle new branches, taking the total number of branches in the country to 520, and further securing our position as the private provider in the country. In parallel, we also introduced planned price hikes across our service portfolio, co to prioritise patient retention and loyalty by sharing the inflationary burden with them. During the quarter, we also Borg Scan's contribution to the country's top-line double versus the same three months of last year, testamen effectiveness of our radiology ramp-up strategy, and the contribution of our house call services remain well abo pandemic averages. Meanwhile, in Jordan, we went ahead with the launch of three new labs, taking the total nu Biolab branches to 26. New branch roll outs have been supporting Biolab's conventional test volumes which pleased to see return to double-digit growth following a Covid-19-related slowdown. In both Nigeria and Su continued to record solid revenue growth in line with recent trends. Here it is important to mention that we exp second quarter results in Sudan to be significantly impacted by the ongoing political and social unrest, with 16 o branches in the country currently shut down. We continue to closely monitor the evolving situation and are confid our management team on the ground has put in place a solid mitigation plan to safeguard our staff, patien operations.

On the cost front, I am pleased to note that we recorded only a moderate increase in raw material costs for the well below the inflation caused by the weakening Egyptian pound. This was possible thanks to successful neg with our main test kit providers who continue to value IDH as a long-term partner. Meanwhile, as part of our e retain staff, we adjusted staff compensation packages to ensure we continue to support our people during these times and remain an employer of choice across all of our markets. Further down the income statement, we r lower margins at all levels of profitability largely reflecting a post-Covid-19 normalization.

Heading into the second half of 2023, we remain on track to deliver on our financial and operational targets for th am particularly looking forward to the launch of our first branch in Saudi Arabia, which is currently sched September 2023. Meanwhile, across our current markets our priorities remain unchanged as we continue to navi ongoing macroeconomic turbulence to drive further conventional revenue growth, safeguard our margins, and co deliver world-class quality to our patients. In Egypt, we are planning to roll out several more branches as t progresses, with a particular focus on growing our radiology network to capitalise on the strong momentum c enjoyed by the segment.

In light of our strong start to the year and the solid strategies in place, we are looking to record year-on-year conv revenue growth of around 30% in FY 2023."

- End -

Analyst and Investor Call Details

An analyst and investor call will be hosted at 1pm (UK) | 3pm (Egypt) on Monday, 5 June 2023. You can registe call by clicking on this link, and you may dial in using the conference call details below:

•€€€€€ **Webinar ID:** 939 3911 9373

•€€€€€ **Webinar Passcode:** 756126

For more information about the event, please contact: amr.amin@cicapital.com

About Integrated Diagnostics Holdings (IDH)

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of pathol radiology tests to patients in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Bo and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and E (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as internationally recognised accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 552 bran of 31 December 2022, IDH served over 8.7 million patients and performs more than 32.7 million tests in 2022. continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable plat efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consume and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standar on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on t since May 2021 (ticker: IDHC.CA).

Shareholder Information

LSE: IDHC.L

EGX: IDHC.CA

Bloomberg: IDHC:LN

Listed on LSE: May 2015

Listed on EGX: May 2021

Shares Outstanding: 600 million

Contact

Nancy Fahmy

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 | nancy.fahmy@idhcorp.com

Forward-Looking Statements

These results for the quarter ended 31 March 2023 have been prepared solely to provide additional inform shareholders to assess the group's performance in relation to its operations and growth potential. These results shoul relied upon by any other party or for any other reason. This communication contains certain forward-looking staten forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by of such words and phrases as "according to estimates", "aims", "anticipates", "assumes", "believes", "could", "es "expects", "forecasts", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the kn of", "will", "would" or, in each case their negatives or other similar expressions, which are intended to identify a state forward-looking. This applies, in particular, to statements containing information on future financial results, p expectations regarding business and management, future growth or profitability and general economic and re conditions and other matters affecting the Group.

Forward-looking statements reflect the current views of the Group's management ("Management") on future events, w based on the assumptions of the Management and involve known and unknown risks, uncertainties and other factors cause the Group's actual results, performance or achievements to be materially different from any future results, perfo or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrenc assumption could cause the Group's actual financial condition and results of operations to differ materially from, or fai expectations expressed or implied by, such forward-looking statements.

The Group's business is subject to a number of risks and uncertainties that could also cause a forward-looking st estimate or prediction to differ materially from those expressed or implied by the forward-looking statements containe communication. The information, opinions and forward-looking statements contained in this communication speak only date and are subject to change without notice. The Group does not undertake any obligation to review, update, conf release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that relation to the content of this communication.

Important notice: In the Company's earnings releases covering the five quarters starting from Q4 2021 ending Q4 2022, management had opted to present Alternative Performance Measures (APM) alongside compliant figures as outlined on page 2 of the Company's FY 2022 Earnings Release. Starting in Q1 2023, the material insignificance of Covid-19-related revenues on consolidated results, the Company will only IFRS-compliant figures. It is worth noting that revenues for the comparable period (Q1 2022), include conc fees amounting to EGP 63 million paid by Biolab as part of its agreement with QAIA and Aqaba Por

Group Operational & Financial Review

i. Revenue and Cost Analysis

Consolidated Revenue

IDH started the year on a strong note, recording **conventional revenues** of EGP 915 million in Q1 2023 impressive 43% from the same three months of last year. Sustained top-line growth was driven by increase Group's average revenue per test, which increased by 27% to EGP 114 in Q1 2023 from EGP 90 in Q1 2022, as in test volumes which increased 12% year-on-year. It is important to note that this quarter's top-line partially refl translation effect resulting from the multiple devaluations of the Egyptian pound throughout FY 2022.

On a **consolidated level,** IDH recorded revenues of EGP 915 million in Q1 2023, down 22% year-on-year comp EGP 1,180 million Q1 2022 when consolidated results had included a significant contribution from IDH's Covid-19 offering impacting Egyptian and Jordanian operations.

Revenue Analysis

	Q1 2022	Q1 2023	%
Total revenue (EGP mn)	**1,180**	**915**	***-22%***
Conventional revenue (EGP mn)	*640*	*915*	*43%*
Total Covid-19-related revenue (EGP mn)	*540*	-	-
Contribution to Consolidated Results			
Conventional revenue	54%	100%	
Total Covid-19-related revenue	46%	-	
Test Volume Analysis			
Total tests (mn)	**8.4**	**8.0**	***-4%***
Conventional tests performed (mn)	7.1	8.0	*12%*
Total Covid-19-related tests performed (mn)	1.3	-	-
Contribution to Consolidated Results			
Conventional tests performed	85%	100%	
Total Covid-19-related tests performed	15%	-	
Revenue per Test Analysis			
Total revenue per test (EGP)	**140**	**114**	***-19%***
Conventional revenue per test (EGP)	90	114	*27%*
Covid-19-related revenue per test (EGP)	431	-	-

Revenue Analysis: Contribution by Patient Segment

Contract Segment (63% of Group revenue)
IDH's contract segment recorded conventional revenue of EGP 579 million during the first quarter of 2023, a 46
million in Q1 2022. The increase was driven by a sustained increase in test volumes at the Company's convent
year to reach 6.5 million and was further bolstered by an increase in average revenue per conventional test, wh
Q1 2023.

Walk-in Segment (37% of Group revenue)
In parallel, IDH's walk-in segment also recorded strong conventional revenue growth of 38% in Q1 2023 driven b
test. Conventional test volumes at the segment remained largely stable, recording 1.5 million tests in Q1 202
recorded EGP 337 million, down 37% year-on-year. Lower walk-in revenues for the quarter mainly reflect the hig
contribution made by Covid-19-related testing in the comparable three months of 2022.

It is important to highlight that the average number of tests per patient at both the Company's contract and walk
following a decrease associated with the Covid-19 pandemic. More specifically, test per patients at the contract a
4.3 and 3.6 tests per patient, respectively.

Key Performance Indicators

	Walk-in Segment			Contract Segment	
	1Q22	**1Q23**	**Change**	**1Q22**	**1Q23**
Revenue (EGP mn)	**535**	**337**	***-37%***	**645**	**579**
Conventional Results (EGP mn)	*244*	*337*	*38%*	*396*	*579*
Total Covid-19-related revenue (EGP mn)	*291*	-	-	*250*	-
Patients ('000)	**971**	**422**	***-57%***	**1,678**	**1,517**
% of Patients	*37%*	*22%*		*63%*	*78%*
Revenue per Patient (EGP)	551	798	*45%*	385	381
Tests ('000)	**2,144**	**1,519**	***-29%***	**6,258**	**6,517**
% of Tests	*26%*	*19%*		*74%*	*81%*
Conventional tests ('000)	*1,530*	*1,519*	*-0.7%*	*5,618*	*6,517*
Total Covid-19-related tests ('000)	*614*	-	-	*641*	-

Revenue per Test (EGP)	250	222	*-11%*	103	89
Conventional Revenue per Test (EGP)	160	222	*39%*	70	89
Test per Patient	2.2	3.6	*63%*	3.7	4.3

Revenue Analysis: Contribution by Geography

Egypt (79.9% of Group revenue)

At IDH's home market, Egypt, the Company continued posting strong conventional revenue growth on the back o per test. More specifically, Egypt recorded conventional revenue growth of 33% year-on-year, booking revenues o EGP 549 million one year prior. Throughout the quarter, IDH's Egyptian operations recorded conventional test v 18% year-on-year increase in average revenue per test. Consolidated revenues in Egypt recorded a 17% year-on 2022 when Covid-19-related revenues has significantly boosted the country's consolidated top-line.

Al-Borg Scan

IDH's Egyptian radiology venture, Al Borg Scan, continued its rapid growth trajectory booking revenues of EGI versus Q1 2022. Revenue growth for the quarter was supported by a 37% year-on-year growth in test volumes average revenue per test provided. Al Borg Scan continued to see its contribution to Egypt's revenues grow, nea top-line in Q1 2023. Patient and test volumes continue to be supported by the successful ramp up of IDH's newe FY 2021 and FY 2022. Building on this, the Company is looking to grow its current network of six branches with end 2023.

House Calls

IDH's house call service in Egypt recorded revenue of EGP 114.2 million in the first quarter of the year, contri period. The robust contribution, which stands well above IDH's pre-pandemic averages, was recorded despite de offering falling to near zero during the quarter.

Wayak

Wayak recorded a 16% year-on-year increase in the number of orders, which came in at 40 thousand in Q1 202 year. EBITDA losses for the quarter recorded EGP 0.4 million, a decline of 21% versus losses recorded in Q expected to decrease further in the coming months as management's strategic efforts continue to pay off.

Detailed Egypt Revenue Breakdown

EGP mn	Q1 2022	Q1 2023	
Total Revenue	**879**	**731**	*-1*
Conventional Revenue	549	731	*3*
Radiology Revenue	17	28	*6*
Total Covid-19-related Revenue	330	-	
Contribution to Consolidated Results			
Conventional revenue	62%	100%	
Radiology revenue	*1.9%*	*3.8%*	
Total Covid-19-related revenue	38%	-	

Jordan (15.8% of Group revenue)

IDH's Jordanian subsidiary, Biolab, recorded solid conventional revenue year-on-year growth of 12% in JOD te year-on-year) supported by higher test volumes for the quarter of 12%. On a consolidated level, in EGP terms, B in revenue for the quarter reflecting the high base effect resulting from results in Q1 2022 having included a sign related offering. Similarly, in JOD terms, Biolab's consolidated revenues declined 73% year-on-year.

Detailed Jordan Revenue Breakdown

EGP mn	Q1 2022	Q1 2023	
Total Revenue	**281**	**144**	**-48**
Conventional Results	70	144	*10*
Total Covid-19-related Revenues (PCR and Antibody)	210	-	
Contribution to Consolidated Results			
Conventional Results	25%	100%	
Total Covid-19-related Revenue (PCR and Antibody)	75%	-	

Nigeria (3.4% of revenue)

Echo-Lab, IDH's Nigerian subsidiary, saw its revenue for the first quarter of the year more than double to record E in Q1 2022. In local currency terms, revenue expanded a solid 26% year-on-year. Top-line growth for the quar average revenue per test expanded versus the same three months of 2022. More specifically, total tests perform year. Meanwhile, average revenue per test increased 80% year-on-year in EGP terms and 9% year-on-year boasts 12 fully operational branches throughout the country, up from 10 branches as of 31 March 2022.

Sudan (1.0% of revenue)

IDH's operations in Sudan recorded revenue growth in EGP terms of 55% reflecting a 119% year-on-ye the country. In SDG terms, revenues were up by 11% supported by a 57% year-on-year rise in averag As at 31 March 2023, IDH's branches in the country stood at 18 up from 17 this time last year. IDH ma evolving situation in the country and a detailed emergency response plan is in place to safeguard ID IDH's 18 branches in the country have temporarily halted operations. Only two of the 18 branches currently operational.

Revenue Contribution by Country

	Q1 2022
Egypt Revenue (EGP mn)	**879**
Conventional (EGP mn)	*549*
Radiology Revenue	*17*
Covid-19-related (EGP mn)	*330*
Egypt Contribution to IDH Revenue	*74.5%*
Jordan Revenue (EGP mn)	**281**
Conventional (EGP mn)	*70*
Covid-19-related (EGP mn)	*210*
Jordan Revenues (JOD mn)	**12.5**
Jordan Revenue Contribution to IDH Revenue	*23.8%*
Nigeria Revenue (EGP mn)	**15**
Nigeria Revenue (NGN mn)	**371**
Nigeria Contribution to IDH Revenue	*1.3%*
Sudan Revenue (EGP mn)	**5.7**
Sudan Revenue (SDG mn)	**152**
Sudan Contribution to IDH Revenue	*0.5%*

Average Exchange Rate

	Q1 2022
USD/EGP	16.5
JOD/EGP	23.2
NGN/EGP	0.04
SDG/EGP	0.04

Patients Served and Tests Performed by Country

	Q1 2022
Egypt Patients Served (mn)	2.0
Egypt Tests Performed (mn)	7.3
Conventional tests (mn)	*6.5*
Covid-19-related tests (mn)	*0.8*
Jordan Patients Served (k)	552
Jordan Tests Performed (k)	991
Conventional tests (k)	*519*
Covid-19-related tests (k)	*472*
Nigeria Patients Served (k)	33
Nigeria Tests Performed (k)	62
Sudan Patients Served (k)	28
Sudan Tests Performed (k)	47
Total Patients Served (mn)	**2.6**
Total Tests Performed (mn)	**8.4**

Branches by Country

	31 March 2022	3
Egypt	472	
Jordan	21	
Nigeria	10	
Sudan	17	
Total Branches	**520**	

-Cost of Sales

Cost of sales dropped 9% year-on-year in Q1 2023 to book EGP 591 million. The decline in cost of sales for th
year-on-year decline in raw material expenses coupled with lower Covid-19-related costs for the three-month peri

Cost of Sales Breakdown as a Percentage of Revenue

	Q1 2022	Q1 2023
Raw Materials	21.4%	20.2%
Conventional raw material costs as % of conventional revenues	*17.7%*	*20.2%*
Covid-19-related raw material costs as % of Covid-19-related revenues	*25.6%*	
Wages & Salaries	14.1%	20.7%
Depreciation & Amortisation	5.5%	9.7%
Other Expenses	14.0%	13.9%
Total	**55.0%**	**64.5%**

Raw material costs including the cost of specialized analysis at other laboratories (31% of consolidated largest contributor to cost of sales during the quarter, recording EGP 185 million compared to EGP 253 million raw materials came in at 20.2%, down from 21.4% in the same period of the previous year. The decline wholly r Covid-19-related test kits purchased during Q1 2022, when demand for IDH's Covid-19-related test offering w prices, it is important to note that the Company did register a rise in average prices for conventional test kits thro back of a weaker EGP and rising inflation. Rising conventional test kit prices were only partially mitigated by fre from one of IDH's largest suppliers, Siemens.

Wages and salaries including employee share of profits (32% share of consolidated cost of sales) made during the first quarter of 2023, increasing 14% year-on-year to book EGP 190 million versus EGP 167 million i and salaries for the period was primarily driven by increases in salaries and wages in Egypt, both due to highe adjustments to partially compensate for rising inflation as well as extra staffing costs to support the rollout of n also in part reflected an increase in Jordanian salaries due to the translation impact as a result of the devaluation Finally, wages and salaries in Nigeria also contributed to consolidated wages and salaries expansion due to ad annual salary increases.

Direct Wages and Salaries by Region

	Q1 2022	Q1 2023
Egypt (EGP mn)	127.8	141.1
Jordan (EGP mn)	34.0	39.1
Jordan (JOD mn)	1.5	0.9
Nigeria (EGP mn)	3.7	7.5
Nigeria (NGN mn)	92.4	113.5
Sudan (EGP mn)	1.1	2.0
Sudan (SDG mn)	29.5	38.0

Direct depreciation and amortization costs (15% of consolidated cost of sales) for the period booked EGP from EGP 64 million in Q1 2022. Depreciation and amortization expenses witnessed a notable increase from the s due to the rollout of new branches across IDH's network, as the Company launched 56 new branches, 24 of which 2023.

Other expenses (22% of consolidated cost of sales) for the quarter decreased 23% year-on-year, reaching E other expenses for the period came on the back of increased repair & maintenance costs and cleaning costs, whi 29% of overall other expenses for the quarter. Increases in repair & maintenance costs and cleaning costs v additional branches across IDH's network.

Gross Profit

IDH's gross profit booked EGP 325 million during Q1 2023, down 39% compared to the same period of the pr margin on revenue came in at 35% decreasing 10 percentage points year-on-year. The drop in gross profitability post-Covid-19 normalisation in IDH's test mix, as well as the previously discussed cost increases largely related to

Selling, General and Administrative Expenses

Total SG&A outlays recorded during Q1 2023 amounted to EGP 196 million, increasing 45% year-on-year. As SG&A expenses came in at 21% compared to 11% in Q1 2022. Increases in SG&A expenses are mainly attributa

- €€€ An increase in wages and salaries primarily due to an increase in IDH's Board of Directors remunera member during the second quarter of 2022, as well as increased salaries in Nigeria to support the hire of
- €€€ An increase in accounting fees related to the external auditor "PwC", reflecting both an increase in t devaluation of the EGP versus the same period of last year (average rate in Q1 2023 was 30.5 EGP/USD
- €€€ Increased consulting fees related to the Company's 2023 sustainability report. Additionally, one-off ex agreement executed in 2023 and legal fees related to the Pakistan transaction. It is important to note tha several devaluations throughout 2022 in IDH's home market of Egypt.
- €€€ Higher marketing and advertisement expenses, which increased 43% year-on-year to reach EGP 32 m Q1 2022. Increases in advertising expenses were the result of marketing efforts aimed at expediting the well as supporting the rollout of new branches in IDH's network.
- €€€ During Q1 2023, IDH recorded other income of EGP 5 million versus other expenses of EGP 1 million 2022. The figure is partially related to a EGP 1.3 million liability pertaining to a contract with Siemens t Park branch with PET-CT equipment, which had weighed down other income in the corresponding period

Selling, General and Administrative Expenses

ii. Balance Sheet Analysis

Assets

Property, Plant and Equipment

IDH recorded gross property, plant and equipment (PPE) of EGP 2,425 million as at 31 March 2023, up from EG
The rise in CAPEX as a share of revenues during Q1 2023 is partially attributable to the EGP 42 million spent on
as the EGP 134 million translation effect (associated with Jordan, Sudan, and Nigeria) which resulted from the
the past twelve months.

Total CAPEX Addition Breakdown - Q1 2023

	EGP mn	% of Revenue
Leasehold Improvements/new branches	42.0	4.6%
Al-Borg Scan Expansion	41.7	4.6%
Total CAPEX Additions Excluding Translation	**83.8**	**9.2%**
Translation Effect	133.6	14.6%
Total CAPEX Additions	**217.4**	**23.7%**

Accounts Receivable and Provisions

As at 31 March 2023, IDH booked accounts receivable of EGP 467 million, up from EGP 395 million as of 31 Dec
Days on Hand (DoH) recorded 122 days, compared to 124 days at year-end 2022.

Provisions for doubtful accounts recorded during Q1 2023 stood at EGP 11 million, up 49% year-on-year from E
provisions reflect the slowdown in collections driven by the current economic condition in Egypt region.

Inventory

As of the end of Q1 2023, IDH recorded an inventory balance of EGP 296 million, up from EGP 265 million as of y
Outstanding (DIO) rose to 144 days from 127 days as at 31 December 2022. The increase in DIO was driven
inventory as a part of its strategy to hedge against ongoing inflation.

Cash and Net Debt/Cash

Cash balances booked as at 31 March 2023 remained relatively stable compared to those as at year-end 2022, re

EGP million	31 Dec 2022	31 Mar 202
T-Bills	296	34
Time Deposits	123	11
Current Accounts	378	34
Cash on Hand	18	1
Total	**816**	**81**

IDH's net debt[14] balance as at 31 March 2023 stood at EGP 424 million, compared to a net debt balance of EGP

EGP million	31 Dec 2022	31 Mar 202
Cash and Financial Assets at Amortised Cost[15]	816	81
Lease Liabilities Property	(727)	(782
Total Financial Liabilities (Short-term and Long-term)	(335)	(278
Interest Bearing Debt ("Medium Term Loans")[16]	(127)	(177
Net Cash/(debt) Balance	**(374)**	**(424**

Note: Interest Bearing Debt includes accrued interest for each period.

Lease liabilities and financial obligations on property recorded EGP 782 million as at 31 March 2023, up
increase in lease liabilities is primarily due to the rollout of 24 new branches across IDH's network.

Meanwhile, **financial obligations related to equipment** decreased to EGP 278 million, from EGP 335 million
financial obligations related to equipment reflects the early repayment of IDH's contractual obligations with Gener
efforts to limit its foreign currency exposure. To finance the settlement, IDH utilized a bridge loan facility, with hal
the other half provided by a loan from Ahly United Bank - Egypt.

Finally, **interest bearing debt** recorded EGP 163 million, up from EGP 117 million as at year-end 2022. The incre
driven by additional usage of MTL to support Al Borg Scan's expansion. It is worth highlighting that interest-bearin
interest.

Liabilities

Accounts Payable[17]

IDH recorded accounts payable of EGP 277 million as at 31 March 2023, remaining largely stable from the EGP
Simultaneously, the Group's Days Payable Outstanding (DPO) decreased to 140 from 151 as at 31 December 20

Put Option

-End-

INTEGRATED DIAGNOSTICS HOLDINGS plc - "IDH"
AND ITS SUBSIDIARIES

Consolidated Financial Statements

for the quarter ended 31 March 2023

Consolidated statement of financial position as at 31 March 2023

	Notes	31 Mar 2023 EGP'000
Assets		
Non-current assets		
Property, plant and equipment	4	1,413,485
Intangible assets and goodwill	5	1,732,745
Right of use assets	6	677,726
Financial assets at fair value through profit and loss	7	22,961
Total non-current assets		**3,846,917**
Current assets		
Inventories		296,363
Trade and other receivables	8	611,033
Financial assets at amortized cost	9	257,668
Cash and cash equivalents	10	555,373
Total current assets		**1,720,437**
Total assets		**5,567,354**
Equity		
Share capital		1,072,500
Share premium reserve		1,027,706
Capital reserves		(314,310)
Legal reserve		51,641
Put option reserve		(298,406)
Translation reserve		(61,726)
Retained earnings		955,990
Equity attributable to the owners of the Company		**2,433,395**
Non-controlling interests		406,714
Total equity		**2,840,109**
Non-current liabilities		
Provisions		3,538
Borrowings	13	79,560
Other financial obligations	15	892,894
Non-current put option liability	14	56,992
Deferred tax liabilities	19-C	323,123
Total non-current liabilities		**1,356,107**
Current liabilities		
Trade and other payables	11	694,177
Other financial obligations	15	167,515
Current put option liability	12	241,414
Borrowings	13	83,320
Current tax liabilities		184,712
Total current liabilities		**1,371,138**
Total liabilities		**2,727,245**
Total equity and liabilities		**5,567,354**

The accompanying notes form an integral part of these consolidated financial statements.

These condensed consolidated interim financial information were approved and authorized for issue by the Board of Directors and signed on their
2023 by:

Dr. Hend El Sherbini
Chief Executive Officer

Hussein Choucri
Independent Non-Executive Direc

Consolidated income statement for the quarter ended 31 March 2023

	Notes	31 Ma EG
Revenue	22	91
Cost of sales		(59
Gross profit		**32**
Marketing and advertising expenses		(6
Administrative expenses	17	(12
Impairment loss on trade and other receivable		(1
Other Income		
Operating profit		**12**
Finance costs	18	(4
Finance income	18	12
Net finance income /(costs)		8
Profit before income tax		**21**
Income tax expense	19-B	(4
Profit for the year		**16**
Profit attributed to:		
Owners of the Company		17
Non-controlling interests		(
		16
Earnings per share		
Basic and diluted	21	

The accompanying notes form an integral part of these consolidated financial statements.

Consolidated statement of comprehensive income for the quarter ended 31 March 2023

	31 Mar EGP
Net profit for the year	**168**
Other comprehensive income:	
Items that may be reclassified to profit or loss:	
Exchange difference on translation of foreign operations	32
Other comprehensive income for the period, net of tax	**32**
Total comprehensive income for the period	**200**
Attributable to:	
Owners of the Company	87

Non-controlling interests	113
	200

The accompanying notes form an integral part of these consolidated financial statements.

Consolidated statement of cash flows for the quarter ended 31 March 2023

	Note
Cash flows from operating activities	
Profit before tax	
Adjustments for:	
Depreciation of property, plant and equipment	
Depreciation of right of use assets	
Amortisation of intangible assets	
Gain on disposal of Property, plant and equipment	
Impairment in trade and other receivables	
Impairment in goodwill	
Interest income	18
Interest expense	18
Bank Charges	
Equity settled financial assets at fair value	
ROU Asset/Lease Termination	
Hyperinflation	18
Unrealised foreign currency exchange loss	18
Change in Provisions	
Change in Inventories	
Change in trade and other receivables	
Change in trade and other payables	
Net cash generated from operating activities	
Cash flows from investing activities	
Proceeds from sale of Property, plant and equipment	
Interest received on financial asset at amortised cost	
Payments for acquisition of property, plant and equipment	4
Payments for acquisition of intangible assets	5
Payments for the purchase of financial assets at amortized cost	
Proceeds for the sale of financial assets at amortized cost	
Net cash generated from/(used in) investing activities	
Cash flows from financing activities	
Proceeds from borrowings	
Repayments of borrowings	
Payment of finance lease liabilities	
Interest paid	
Bank charge paid	
Net cash flows used in financing activities	
Net (decrease) increase in cash and cash equivalents	
Cash and cash equivalents at the beginning of the year	
Effect of exchange rate	
Cash and cash equivalents at the end of the period	10

Non-cash investing and financing activities disclosed in other notes are:

- •€€€€€ Acquisition of right-of-use assets - note 26
- •€€€€€ Property, plant and equipment - note 11
- •€€€€€ Put option liability - note 23 and 25

The accompanying notes form an integral part of these consolidated financial statements.

Consolidated statement of changes in equity for the quarter ended 31 March 2023

EGP'000	Share Capital	Share premium	Capital reserve	Legal reserve*	Put option reserve	Translation reserve	Retained earnings	Total attributed the owne of the Compar
As at 1 January 2023	**1,072,500**	**1,027,706**	**(314,310)**	**51,641**	**(490,695)**	**24,173**	**783,081**	**2,154**
Profit / (loss) for the year	-	-	-	-	-	-	172,909	172
Other comprehensive (expense)/ income for the year	-	-	-	-	-	(85,899)	-	(85,
Total comprehensive income	**-**	**-**	**-**	**-**	**-**	**(85,899)**	**172,909**	**87**
Transactions with owners in their capacity as owners Contributions and distributions								
Movement in put option liabilities for the year	-	-	-	-	192,289	-	-	192
Total	**-**	**-**	**-**	**-**	**192,289**	**-**	**-**	**192**
At at 31 March 2023	**1,072,500**	**1,027,706**	**(314,310)**	**51,641**	**(298,406)**	**(61,726)**	**955,990**	**2,433**
As at 1 January 2022	**1,072,500**	**1,027,706**	**(314,310)**	**51,641**	**(956,397)**	**150,730**	**1,550,976**	**2,582**
Profit for the year	-	-	-	-	-	-	296,609	296
Other comprehensive loss for the year	-	-	-	-	-	13,941	-	13
Total comprehensive income	**-**	**-**	**-**	**-**	**-**	**13,941**	**296,609**	**310**
Transactions with owners in their capacity as owners Contributions and distributions								
Movement in put option liabilities for the year	-	-	-	-	(170,940)	-	-	(170,
Impact of hyperinflation	-	-	-	-	-	-	1,570	1
Total	**-**	**-**	**-**	**-**	**(170,940)**	**-**	**1,570**	**(169,**
At 31 March 2022	**1,072,500**	**1,027,706**	**(314,310)**	**51,641**	**(1,127,337)**	**164,671**	**1,849,155**	**2,724**

* Under Egyptian Law each subsidiary must set aside at least 5% of its annual net profit into a legal reserve until such time that this represents 50% of each subsidiary
distributable to the owners of the Company

The accompanying notes form an integral part of these consolidated financial statements.

(In the notes all amounts are shown in Egyptian Pounds "EGP'000" unless otherwise stated)

1. Reporting entity

Integrated Diagnostics Holdings plc "IDH" or "the Company" is a Company which was incorporated in Jersey on December 2014 and established according to the provisions of the Companies (Jersey) Law 1991 under Registere No. 117257. These condensed consolidated interim financial information as at and for the three months ended 3 March 2023 comprise the Company and its subsidiaries (together referred as the 'Group'). The Company is a dua listed entity, in both London Stock Exchange (since 2015) and in the Egyptian Exchange (during May 2021).

The principal activities of the Company and its subsidiaries (together "The Group") include investments in all types the healthcare field of medical diagnostics (the key activities are pathology and Radiology related tests), either throug acquisitions of related business in different jurisdictions or through expanding the acquired investments they have. Th key jurisdictions that the Group operates are in Egypt, Jordan, Nigeria and Sudan.

The Group's financial year starts on 1 January and ends on 31 December of each year.
These condensed consolidated interim financial information were approved for issue by the Directors of the Compa on 30 May 2023.

2. Basis of preparation

A. Statement of compliance

These condensed consolidated interim financial information have been prepared as per IAS 34 'Interim Financ Reporting' (As adopted by the IASB). as the accounting policies adopted are consistent with those of the previo financial year ended 31 December 2022 and corresponding interim reporting period.

These condensed consolidated interim financial information do not include all the information and disclosures in th annual consolidated financial Statement, and should be read in conjunction with the financial Statement published a at and for the year ended 31 December 2022 which is available at www.idhcorp.com,. In addition, results of the thre month period ended 31 March 2023 are not necessary indicative for the results that may be expected for the financ year ending 31 December 2023.

B. Basis of measurement

The condensed consolidated interim financial information has been prepared on the historical cost basis except whe adopted IFRS mandates that fair value accounting is required which is related to the financial assets and liabiliti measured at fair value.

C. Functional and presentation currency

These condensed consolidated interim financial information is presented in Egyptian Pounds (EGP'000). The functior currency of the majority of the Group's entities is the Egyptian Pound (EGP) and is the currency of the prima economic environment in which the Group operates.

The Group also operates in Jordan, Sudan and Nigeria and the functional currencies of those foreign operations are th local currencies of those respective territories, however due to the size of these operations, there is no significa impact on the functional currency of the Group, which is the Egyptian Pound (EGP).

3. Significant accounting policies

In preparing these condensed consolidated interim financial information, the significant judgments made by th management in applying the Group's accounting policies and the key sources of estimation uncertainty were the san as those that were applied to the consolidated financial information for the year ended 31 December 2022."Th preparation of these condensed consolidated interim financial information requires management to make judgement estimates and assumptions that affect the application of accounting policies and the reported amounts of asset liabilities, income and expense. Actual results may differ from these estimates. Information about significant areas estimation uncertainty and critical judgement in applying accounting policies that have the most significant effect o the amount recognised in the condensed consolidated interim financial statement is described in note 2.2 of th annual consolidated financial information published for the year ended 31 December 2022. In preparing thes condensed consolidated interim financial information, the significant judgments made by the management in applyin the Group's accounting policies and the key sources of estimation uncertainty were the same as those that we applied to the consolidated financial information for the year ended 31 December 2022".

4. Property, plant and equipment

	Land & buildings	Medical, electric & information system equipment	Leasehold improvements	Fixtures, fittings & vehicles	Pr u cons
Cost					
At 1 January 2023	**426,961**	**1,111,867**	**507,442**	**133,195**	
Additions	-	29,937	5,051	10,172	
Disposals	-	(825)	(317)	(601)	
Transfers	-	-	8,948	-	
Exchange differences	5,158	74,204	37,095	16,116	
At 31 March 2023	**432,119**	**1,215,183**	**558,219**	**158,882**	

Depreciation				
At 1 January 2023	**61,578**	**513,869**	**261,705**	**55,254**
Depreciation for the period	1,768	38,330	19,761	3,858
Disposals	-	(501)	(262)	(403)
Exchange differences	901	38,044	19,029	9,611
At 31 March 2023	**64,247**	**589,742**	**300,233**	**68,320**
Net book value at 31 March	**367,872**	**625,441**	**257,986**	**90,562**
At 31 December 2022	**365,383**	**597,998**	**245,737**	**77,941**

5. Intangible assets and goodwill

Intangible assets represent goodwill acquired through business combinations and brand names.

	Goodwill	**Brand name**	**So**
Cost			
Balance at 1 January 2023	**1,291,823**	**395,551**	
Additions	-	-	
Effect of movements in exchange rates	20,320	7,588	
Balance at 31 March 2023	**1,312,143**	**403,139**	
Amortisation and impairment			
Balance at 1 January 2023	**6,373**	**381**	
Amortisation	-	-	
Effect of movements in exchange rates	-	-	
Balance at 31 March 2023	**6,373**	**381**	
Carrying amount			
Balance at 31 December 2022	**1,285,450**	**395,170**	
Balance at 31 March 2023	**1,305,770**	**402,758**	

Goodwill impairment reviews are undertaken annually or more frequently if events or changes in circumstanc indicate a potential impairment. No indicators of impairment have been identified during the three months ended 3 March 2023.

6. Right-of-use assets

	31 March 2023
Balance at 1 January	**622,975**
Addition for the period / year	**44,903**
Depreciation charge for the period / year	**(32,938)**
Terminated contracts	**(3,584)**
Exchange differences	**46,370**
Balance	**677,726**

7. Financial asset at fair value through profit and loss

	31 March 2023
Equity investments*	**22,961**
	22,961

* On August 17, 2017, Almakhbariyoun AL Arab (seller) has signed IT purchase Agreement with JSC Mega La (Buyer) to transfer and install the Laboratory Information Management System (LIMS) for a purchase pric amounted to USD 400 000, which will be in the form of 10% equity stake in JSC Mega Lab. In case the valuatio of the project is less or more than USD 4,000,000, the seller stake will be adjusted accordingly, in a way that th seller equity stake shall not fall below 5% of JSC Mega Lab.

- ownership percentage in JSC Mega Lab at the transaction date on April 8, 2019, and as of March 31, 202 was 8.25%.
- On April 8, 2019, Al Mokhabariyoun Al Arab (Biolab) has signed a Shareholder Agreement with JSC Meg Lab and JSC Georgia Healthcare Group (CHG), whereas, BioLab Shall have a put option, exercisable with 12 months immediately after the expiration of five(5) year period from the signing date, which allows BioLa stake to be bought out by CHG at a price of the equity value being USD 400,000 plus 15% annual Interre Rate of Return (IRR). In case the Management Agreement or the Purchase Agreement and/or the Servic level Agreement is terminated/cancelled within 6 months period from the date of such termination/cancellatio CHG shall have a call option, which allows the CHG to purchase Biolab's Strake in JSC Megalab having valu of USD 400,000.00 plus 20% annual Interred Rate of Return (IRR). If JCI accreditation is not obtaine immediately after the expiration of the 12 months period, CHG shall have a call option (the Accreditation C option), exercisable within 6 months period, allowing CHG to purchase BioLab's Shares in JSC Mega Lab at price of the equity value of USD 400,00.00 plus the 20% annual IRR.

8. Trade and other receivables

	31 M
Trade receivables - net	46
Prepayments	35
Due from related parties note (16)	5
Other receivables	99
Accrued revenue	2
	61

9. Financial assets at amortised cost

	31
Term deposits (more than 3 months)	11
Treasury bills (more than 3 months)	14
	25

The maturity date of the treasury bills and Fixed-term deposits are between 3-12 months and have average intere rates of EGP, and JOD 18.99% and 5.23% respectively.

10. Cash and cash equivalents

	31 M
Cash at banks and on hand	35
Treasury bills (less than 3 months)	19
Term deposits (less than 3 months)	
	55

11. Trade and other payables

	31 March 2023
Trade payable	277,462
Accrued expenses	210,957

Due to related parties note (16)	**35,490**
Other payables	**114,140**
Deferred revenue	**52,564**
Accrued finance cost	**3,564**
	694,177

12. Current put option liability

	31 March 2023
Put option - Biolab Jordan	**241,414**
	241,414

The accounting policy for put options after initial recognition is to recognise all changes in the carrying value of the p option liability within equity.

Through the historic acquisitions of Makhbariyoun Al Arab the Group entered into separate put option arrangements purchase the remaining equity interests from the vendors at of a subsequent date. At acquisition, a put option liabil has been recognised at the net present value of the exercise price of the option.

The option is calculated at seven times EBITDA of the last 12 months minus Net Debt and its exercisable in who starting the fifth anniversary of completion of the original purchase agreement, which fell due in June 2016. Th vendor has not exercised this right at 31 March 2023. It is important to note that the put option liability is treated a current as it could be exercised at any time by the NCI. However,

based on discussions and ongoing business relationship, there is no expectation that this will happen in next 1 months. The option has no expiry date.

13. Loans and borrowings

	Currency	Nominal interest rate	Maturity	31 Ma 2
AUB - Bank	EGP	CBE corridor rate+1%	26 January 2027	**107,**
AUB - Bank	EGP	CBE corridor rate+1%	29 June 2023	**54,**
				162,
Amount held as:				
Current liability				**83,**
Non- current liability				**79,**
				162,

A) In July 2018, AL-Borg lab, one of IDH subsidiaries, was granted a medium term loan amounting to EGP 185 from Ahli United Bank "AUB Egypt" to finance the investment cost related to the expansion into the radiolog segment. As at 31 March 2023 only EGP 179.8 M had been drawn down from the total facility available wi 17m had been repaid. Loan withdrawal availability period was extended till July 2023 and the loan will be fu repaid by January 2027.

The loan contains the following financial covenants which if breached will mean the loan is repayable o demand:

1. The financial leverage shall not exceed 0.7 throughout the period of the loan
"**Financial leverage**": total bank debt divided by net equity

2. The debt service ratios (DSR) shall not be less than **1.35 starting 2020**
"**Debt service ratio**": cash operating profit after tax plus depreciation for the financial year less annua maintenance on machinery and equipment adding cash balance (cash and cash equivalent) divided b total financial payments.

"**Cash operating profit**": Operating profit after tax, interest expense, depreciation and amortisation, calculated as follows: Net income after tax and unusual items adding Interest expense, Depreciatio Amortisation and provisions excluding tax related provisions less interest income and Investment incom and gains from extraordinary items.

"**Financial payments**": current portion of long-term debt including finance lease payments, interes expense and fees and dividends distributions.

3. The current ratios shall not be less than 1.
"**Current ratios**": Current assets divided current liabilities.

The terms and conditions of outstanding loans are as follows:

* As at 31 March 2023 corridor rate 20.25% (2022: 17.25%)

AL- Borg company didn't breach any covenants for MTL agreements.

B) IDH opted to reduce its exposure to foreign currency risk by coming to an agreement with General Electr (GE) for the early repayment of its contractual obligation of USD 5.7 million. As of March 28, 2023, th remaining obligation balance stood at USD 5.0 million, with USD 0.7 million having been repaid since th contract was initiated in 2020. The Group and GE have agreed to settle this balance early for USD 3.5 million, payable in EGP, equivalent to EGP 110 million.

To finance the settlement, IDH utilized a bridge loan facility, with half of the amount (EGP 55 million) bein funded internally and the other half (EGP 55 million) provided by a loan from Ahly United Bank - Egypt, wi due to the date on 29 June 2023.

14. Non-current put option liability

	31 March 2023
Put option liability*	**56,992**
	56,992

* According to the definitive agreements signed on 15 January 2018 between Dynasty Group Holdings Limited a the International Finance Corporation (IFC) related to the Eagle Eye-Echo scan transaction, IFC has the option put it is shares to Dynasty in year 2024. The put option price will be calculated on the basis of the fair market val determined by an independent valuator.

15. Other Financial obligations

	31 March 2023

Financial liability- laboratory equipment	**278,319**
Lease liabilities building	**782,090**
	1,060,409

The financial obligations for the laboratory equipment and building are payable as follows:

		31 March 2023
	Minimum payments	**Intere**
Less than one year	299,559	132,04
Between one and five years	1,001,389	293,11
More than five years	228,482	43,86
	1,529,430	**469,02**

		31 December 2022
	Minimum payments	**Interes**
Less than one year	285,962	137,257
Between one and five years	1,030,750	314,656
More than Five years	227,715	29,618
	1,544,427	**481,531**

Amounts recognised in profit or loss:

	For the three month
	2023
Interest on lease liabilities	**22,323**
Expenses related to short-term lease	**2,676**

16. Related party transactions

The significant transactions with related parties, their nature volumes and balance during the period 31 March 202
are as follows:

Related Party	Nature of transaction	Nature of relationship	Transaction y EG
ALborg Scan (S.A.E)*	Expenses paid on behalf	Affiliate	
International Fertility (IVF)**	Expenses paid on behalf	Affiliate	
H.C Security	Provide service	Entity owned by Company's board member	
Life Health Care	Provided service	Entity owned by Company's CEO	
Dr. Amid Abd Elnour	Put option liability	Bio. Lab C.E.O and shareholder	
	Current account	Bio. Lab C.E.O and shareholder	
International Finance corporation (IFC)	Put option liability	Echo-Scan shareholder	
International Finance corporation (IFC)	Current account	Echo-Scan shareholder	
Integrated Treatment for Kidney Diseases (S.A.E)	Collection Medical Test analysis	Entity owned by Company's CEO	
HENA HOLDINGS LTD	shareholders' dividends deferral agreement	shareholder	
ACTIS IDH LIMITED	shareholders' dividends deferral agreement	shareholder	

Related party transactions (continued)

Related Party	Nature of transaction	Nature of relationship	Transaction yo EGP
ALborg Scan (S.A.E)*	Expenses paid on behalf	Affiliate	
International Fertility (IVF)**	Expenses paid on behalf	Affiliate	
H.C Security	Provide service	Entity owned by Company's board member	
Life Health Care	Provided service	Entity owned by Company's CEO	
Dr. Amid Abd Elnour	Put option liability	Bio. Lab C.E.O and shareholder	
	Current account	Bio. Lab C.E.O and shareholder	
International Finance corporation (IFC)	Put option liability	Echo-Scan shareholder	
International Finance corporation (IFC)	Current account	Echo-Scan shareholder	
Integrated Treatment for Kidney Diseases (S.A.E)	Rental income Medical Test analysis	Entity owned by Company's CEO	
Dr. Hend El Sherbini	Loan arrangement	CEO	

HENA HOLDINGS LTD	shareholders' dividends deferral agreement	shareholder
ACTIS IDH LIMITED	shareholders' dividends deferral agreement	shareholder

* ALborg Scan is a company whose shareholders include Dr. Moamena Kamel (founder of IDH subsidiary A Mokhtabar Labs).

** International Fertility (IVF) is a company whose shareholders include Dr. Moamena Kamel (founder of ID subsidiary Al-Mokhtabar Labs).

Related party transactions (continued)

Compensation of key management personnel of the Group

The amounts disclosed in the table are the amounts recognised as an expense during the reporting period related key management personnel.

	31 March 2023
Short-term employee benefits	20,192
	20,192

17. General and administrative expenses

	For the three months ended 2023
Wages and salaries	**51,762**
Depreciation	**8,459**
Amortisation	**1,554**
Other expenses	**64,708**
Total	**126,483**

18. Net finance cost

	For the three month 2023
Finance income	
Interest income	15,168
Net foreign exchange gain	109,320
Gain on hyperinflationary net monetary position	-
Total finance income	**124,488**
Finance cost	
Bank charges	(2,408)
Interest expense	(40,387)
Total finance cost	**(42,795)**
Net finance income	**81,693**

19. Tax

A) Tax expense

Tax expense is recognised based on management's best estimate of the weighted-average annual income t rate expected for the full financial year multiplied by the pre-tax income of the interim reporting period.

B) Income tax

Amounts recognised in profit or loss as follow:

	For the three months ende 2023
Current tax:	
Current period	(41,136)
Deferred tax:	
Deferred tax arising on undistributed reserves in subsidiaries	190
Relating to origination and reversal of temporary differences	(1,171)
Total Deferred tax expense	**(981)**
Tax expense recognised in profit or loss	**(42,117)**

Tax (continued)

C) Deferred tax liabilities

Deferred tax relates to the following:

	31 Marcl 202
Property, plant and equipment	**(34,409**
Intangible assets	**(112,094**

Undistributed reserves from Group subsidiaries	**(176,681**
Provisions and financial obligation	**6**
Net deferred tax liabilities	**(323,123**

20. Financial instruments

The Group has reviewed the financial assets and liabilities held at 31 March 2023. It has been deemed th the carrying amounts for all financial instruments are a reasonable approximation of fair value. All financi instruments are deemed Level 3.

Contingent liabilities

As required by article 134 of the labour law on Vocational Guidance and Training issued by the Egyptian Governme in 2003, Al Borg Laboratory Company and Al Mokhtabar Company for Medical Labs are required to conform to t requirements set out by that law to provide 1% of net profits each year into a training fund. Integrated Diagnosti Holdings plc have taken legal advice and considered market practice in Egypt relating to this and more specifica whether the vocational training courses undertaken by Al Borg Laboratory Company, Al Mokhtabar Company f Medical Labs and Integrated medical analysis suggest that obligations have been satisfied through traini programmes undertaken in-house by those entities. Since the issue of the law on Vocational Guidance and Trainir Al Borg Laboratory Company, Al Mokhtabar Company for Medical Labs and Integrated medical analysis have not be requested by the government to pay or have voluntarily paid any amounts into the external training fund. Should claim be brought against Al Borg Laboratory Company, Al Mokhtabar Company for Medical Labs and Integrat medical analysis, an to up to 46m EGP could become payable, however this is not considered probable.

21. Earnings per share

	For the three mor
	2023
Profit attributed to owners of the parent	**172,909**
Weighted average number of ordinary shares in issue	**600,000**
Basic and diluted earnings per share	**0.29**

The Company has no potential diluted shares as at 31 March 2023 and 31 March 2022, therefore; the earnings p diluted share are equivalent to basic earnings per share.

22. Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operati decision-maker. The chief operating decision-maker who is responsible for allocating resources and assessi performance of the operating segments, has been identified as the steering committee that makes strategic decision

The Group has four operating segments based on geographical location rather than two operatir segments based on service provided, as the Group's Chief Operating Decision Maker (CODM) reviews th internal management reports and KPIs of each geography.

The Group operates in four geographic areas, Egypt, Sudan, Jordan, and Nigeria. As a provider of medic diagnostic services, IDH's operations in Sudan are not subject to sanctions. The revenue split, EBITDA sp (being the key profit measure reviewed by CODM) net profit and loss between the four regions is set o below.

	Revenue by geographic loca		
For the three months ended	**Egypt region**	**Sudan region**	**Jordan region**
31 March 2023	**731,040**	**8,780**	**144,473**
31 March 2022	879,490	5,672	280,514

	EBITDA by geographic loca		
For the year ended	**Egypt region**	**Sudan region**	**Jordan region**
31 March 2023	**197,947**	**1,622**	**35,832**
31 March 2022	395,056	86	74,312

Segment reporting (continued)

	Net profit / (loss) by geo		
For three-month period ended	**Egypt region**	**Sudan region**	**Jorda regio**
31 March 2023	**171,237**	**4,072**	**6,39**
31 March 2022	269,516	2,756	45,0

	Revenue by type For the three months ended 31 March		For th
	2023	**2022**	**2**
Pathology	**856,436**	1,148,804	
Radiology	**58,855**	31,675	
	915,291	1,180,479	

	Revenue by catego For the three months 31 March
	2023
Walk-in	**336,740**
Corporate	**578,551**
	915,291

Non-current assets by geographic lo

	Egypt region	Sudan region	Jordan region
31 March 2023	**3,073,330**	**17,096**	**614,413**
31 December 2022	3,039,930	14,993	494,244

The operating segment profit measure reported to the CODM is EBITDA, as follows:

	For the three months perio
	2023
Profit from operations	**128,810**
Property, plant and equipment depreciation	**63,717**
Right of use depreciation	**32,938**
Amortisation of Intangible assets	**1,913**
EBITDA	**227,378**

23. Important events

The Central Bank of Egypt increased the interest rate by 200 points, to reach 19.25% instead 17.25%. This was by a decision of the Monetary Policy Committee, according to the meeting held c March 30, 2023

24. Subsequent event

During April 2023, an armed conflict began in Sudan that led to security unrest across the country. Business h been temporarily frozen in the branches of the Sudan Laboratory Company and Ultra Lab until further notic which will greatly affect the profits of the geographical sector in the subsequent period. There is no damage the material assets to date. The Group's management is closely monitoring the situation and is curren evaluating the impact of these events on the Group's business results and activities.

QRFEAPSFDFEDEFA